n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, August 15th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

Vilacto Bio, Inc. (VIBI)

OTC Markets and The Street reported on Vilacto Bio, Inc. (VIBI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Vilacto Bio, Inc. is a biotechnology company listed on the OTCQB. It has developed the now fully patented Lactoactive® (Lactoactive molecule). In manifold studies, Lactoactive® has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. At present, the Company’s products are available on the market as Vilact®. Vilacto Bio has its corporate headquarters in New York, New York.

The Company’s goal is to be the foremost biotechnology company centered on commercializing unique pharmaceutical cosmeceutical products formulated or reformulated with Lactoactive® as nanoparticle according to its patented properties. Vilacto Bio’s aim is to further develop its Lactoactive® molecule for increasing the quality of its retail and medical skin cream products, and also licensing out its Lactoactive® molecule for the pharmaceutical industry.

Lactoactive® is highly refined colostrum, developed to provide first-rate results for people requiring healing or relief from a range of skin issues. Lactoactive® is a refined processing of colostrum combined with hyaluronic acid. During this process, the ingredients attain a much better effect than previously seen. The yield of protein content is as high as 82 percent, versus the normal 50-60 percent. Proteins in Vilact® survive longer without being degraded by enzymes. This enables them to work longer in the skin.

In July, Vilacto Bio announced that it launched its U.S. eCommerce portal. At this site, U.S. consumers can obtain the trademarked skin care line Vilact®, which contains Lactoactive®. Vilacto Bio recently presented its latest product, Vilact Cuticle cream, developed in cooperation with Danish podiatrists. Lactoactive, the ingredient molecule in Vilact Cuticle cream, works to help with skin challenges. Danish podiatrists have demonstrated its use with speedier patient recovery.

Vilacto Bio announced in July that the upgrade of its production facility was completed. The upgrade included an additional storage container, improved mixing machines, as well as an upscale filtration unit. The upgrade allows the Company to boost its production of its Lactoactive® molecule and output.

Vilacto Bio will present at the China (Wuxi) International Industrial Design Expo 2017, which will take place September 21-24, 2017 at the Wuxi region, one of mainland China’s most innovative cities, organized by the Department of Science & Technology. Vilacto Bio will be at this Expo to expand its exposure in Asia, meeting with partners, distributors and investors.

Vilacto Bio, Inc. (VIBI), closed Tuesday's trading session at $1.17, up 2.63%, on 97,788 volume with 45 trades. The average volume for the last 60 days is 9,610 and the stock's 52-week low/high is $0.45/$1.39.

China YCT International Group, Inc. (CYIG)

SquawkBoxStocks, Penny Pick Finders, TerrificPennyStocks, Breaking Bulls, AwesomeStocks, PennyStocks24, Chatter Box Stocks, MyBestStockAlerts, Buzz Stocks, PennyStockCrowd, Marquee Penny Stocks, Penny Stock Rumble, PennyStocksV2, and Planet Pennies reported earlier on China YCT International Group, Inc. (CYIG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

China YCT International Group, Inc is a developer, manufacturer, and distributor of traditional Chinese medicines (TCM). A biotechnology company, it mainly concentrates on producing medicines and selling organic healthcare products. In addition, China YCT is a significant player in the Acer Truncatum oil business. The Company anticipates that this will be a billion-dollar market in the near future.

China YCT International Group has its head office in Sishui County, Shandong Province, China. It lists on the OTC Markets Group’s OTCQB.

The Company engages in developing, manufacturing, and selling its own TCM’s made primarily from ginseng extract, manufacturing and distributing acertruncatumbunge seed oils, and distributing health care supplement products in China.

China YCT International Group announced in May 2017 that it signed an agreement to purchase the Acer Truncatum business from Shandong YCT Group Co. Ltd. The expectation is that this new business will increase sales by a billion U.S. dollars for China YCT in the next 5 years.

Acer Truncatum is a kind of maple. It has 300 species around the world. Acer Truncatum is only available in China.

The Acer Truncatum oil contains 5.8 percent of nervonic acid.  Acer Truncatum is contained in plants, and nervonic acid can undergo extraction from these very economically. After more than 40 years’ research and experiments, the Chinese government approved Acer Truncatum oil as general wood food oil that can be used as a general food oil, such as soybean, corn, olive, as well as other food oils.

Recently, China YCT International Group announced its financial results for the fiscal year ending March 31, 2017. The Company achieved $56,463,164 in revenue. This represents an increase of 18.1 percent or $8,636,056, versus $47,827,108 for the same period the year prior.

The Company achieved net income of $10,054,654. This represents a 19.5 percent or $1,637,885 increase, versus $8,416,769 during the fiscal year ended March 31, 2016.

Mr. Yan Tinghe, China YCT International Group's Chief Executive Officer, said, "The Company's next business goal is to become a leading enterprise in research, cultivation, and production in the domestic and international market for acertruncatum woody edible oils."

China YCT International Group, Inc. (CYIG), closed Tuesday's trading session at $0.51, down 9.73%, on 1,064 volume with 4 trades. The average volume for the last 60 days is 2,842 and the stock's 52-week low/high is $0.046/$0.70.

Abattis Bioceuticals Corp. (ATTBF)

Promotion Stock Secrets, InvestorIntel, CFN Media Group, Goldman Small Cap Research, Stockgoodies, Cannabis Financial Network News, Greenbackers, PennyStocks24, and Information Solutions Group reported earlier on Abattis Bioceuticals Corp. (ATTBF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Abattis Bioceuticals Corp. is a specialty, vertically-integrated biotechnology company. It aggregates, incubates, integrates, and invests in the botanical drug development industry. The Company’s divisions include Biocell Labs, Inc. and Vergence Sales & Marketing, Inc. Through these, the Company develops and licenses natural health products. In addition, its other divisions are Northern Vine Canada, Inc.; North American Bioextracts, Inc.; and Biocube Green Grow Systems Corp. Abattis Bioceuticals has its headquarters in Vancouver, British Columbia.

Abattis has capabilities that support the production and extraction of botanical ingredients for its products; one of which includes cannabis. The Company develops and licenses natural health products, medicines, extractions, and ingredients - some of which will contain cannabinoid compounds.  These are for the biologics, nutraceutical, bioceutical, and cosmetic markets. Furthermore, Abattis has a broad pipeline of high-quality products and intellectual property (IP) for the fast-growing botanical drug market.

Abattis Bioceuticals’ products and services include Botanical Blends & Formulas; CBD Ingredients; Functional Foods & Beverages; Research and Development (R&D); Analytical Services; and Pharma & Nutraceuticals. It has received a Natural Product Number (NPN) approval for Phyto(NOS). This NPN allows it to manufacture and sell Phyto(NOS) in Canada.

Phyto(NOS) has applications in a broad array of food, beverage, and nutraceutical products. Phyto(NOS) is an all-natural, patent-pending formulation. It naturally supports nitric oxide (a vasodilator) levels in the blood stream, supports nitric oxide production, and provides antioxidants.

Abattis Bioceuticals and Northern Vine entered into a Binding Memorandum of Agreement with Experion Biotechnologies to acquire up to 100 percent of Experion Biotechnologies, Inc.  Abattis Management has been centering their efforts on its Northern Vine Lab buildout after receiving their controlled substance dealers license (CSL) last year. Northern Vine Labs has the required licenses and controls in place to legally possess and work with the raw herb (cannabis) and its active ingredients.

Northern Vine will provide analytical R&D and quality control testing on a large assortment of cannabis based products, screening for cannabinoids, terpenes, microbiological contaminants, pesticides and residual solvents. The license also permits it to formulate new products for licensed producers in Canada.

Abattis Bioceuticals signed an exclusive distribution agreement with Suzhou Raybot Material Tech Corp. The Agreement permits Abattis to use Raybot's proprietary extraction technology and to exclusively sell the extraction equipment and services. Raybot has developed a proprietary technology that uses industrial column chromatography to extract and separate a broad spectrum of materials, in a continuous, closed loop system.

Recently, Abattis Bioceuticals announced that its subsidiary, Northern Vine Canada, officially launched its flagship laboratory, having completed its initial successful test analysis. Northern Vine obtained a Health Canada Dealers' License pursuant to the provisions of the Controlled Drugs and Substances Act and the Narcotic Control Regulations. Northern Vine started taking samples from select Licensed Producers (LPs). It is building a sales force to aggressively grow its client base.

Abattis Bioceuticals Corp. (ATTBF), closed Tuesday's trading session at $0.0901, down 9.81%, on 691,162 volume with 120 trades. The average volume for the last 60 days is 265,290 and the stock's 52-week low/high is $0.015/$1.00.

Greystone Logistics, Inc. (GLGI)

Zacks, MarketWatch, and Trading View reported on Greystone Logistics, Inc. (GLGI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Greystone Logistics, Inc. reprocesses and sells recycled plastic, and designs, manufactures, sells, and leases high-quality 100 percent recycled plastic pallets. These provide logistical solutions needed by a wide variety of industries. These industries include food and beverage, agricultural, automotive, chemical, and pharmaceutical and consumer products. Greystone Logistics is the largest 100 percent recycled plastic pallet manufacturer in the United States. A "Green" manufacturing and leasing enterprise, Greystone Logistics is headquartered in Tulsa, Oklahoma.

The Company’s technology, including that utilized in its injection molding equipment, and its proprietary blend of recycled plastic resins and patented pallet designs, enables fast production of high-quality pallets and at lower costs than many processes. The recycled plastic for its pallets helps control material costs. This is while lessening environmental waste.

Greystone Logistics provides cost advantages over users of virgin resin. The excess plastic not used in the production of pallets undergoes reprocessing for resale. The Company’s products include rackable, nestable, display, monoblock, as well as stackable pallets. In addition, its products include picture frame web-top pallets and web-top pallets. Furthermore, the Company sells recycled plastic that undergoes reprocessing into pellet form. It also provides pallet leasing services.

Concerning obtaining or selling resin or excess plastic, Greystone Logistics buys HDPE scrap, pellets, purchings, dust, shavings, and parts. The Company sometimes sells some excess pelletized Santoprene, HDPE and comingled-baled scrap TPU and ABS car bumpers.

Greystone Logistics offers recycled pallets for sale including full picture frame and three skids models and IBC pallets. Plastic pallets last 10-50 times longer than wood; have residual (trade-in) value; are recyclable; have a high coefficient of friction with anti-skid design for top, bottom, and fork lift tine contact; have considerably lower life cycle costs (cost per trip), and are suited for closed loop systems. Plastic pallets have no exposed nails, wood chips, or broken boards on manufacturing or warehouse floors. This prevents fork lift issues.

This past April, Greystone Logistics reported that sales for the three months ended February 28, 2017 totaled $8,693,851 versus $5,280,480 for the prior period. This represents an increase of $3,413,371, or 65 percent.

Sales for the nine months ended February 28, 2017 were $25,759,823 versus $15,270,671 for the prior period. This represents an increase of $10,489,152, or 69 percent. The Company said in April that there continues to be a backlog of sales for a wide range of its products.

Greystone Logistics, Inc. (GLGI), closed Monday's trading session at $0.20, down 13.04%, on 8,300 volume with 3 trades. The average volume for the last 60 days is 14,982 and the stock's 52-week low/high is $0.05/$0.56.

Talon International, Inc. (TALN)

Liquid Tycoon, Penny Pick Finders, Penny Stock MoneyTrain, Penny Stock Pick Alert, Penny Stock Pick Report, PennyStockProphet, Wall Street Mover, TopPennyStockMovers, Greenbackers, Wallstreetlivechat, OtcWizard, PennyStocks24, SecretStockPromo, StockOnion, Super Nova Stock Picks, WePickPennyStocks, Winning Penny Stock Picks, and Super Hot Penny Stocks reported earlier on Talon International, Inc. (TALN), and we report on the Company today, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Talon International, Inc. is a top international supplier of zippers, apparel fasteners, trim, and stretch technology products. It supplies these products to manufacturers of fashion apparel, specialty retailers, mass merchandisers, brand licensees, as well as major retailers globally. Established in 1893, Talon is the world’s original zipper brand.

The Company has its head office in Woodland Hills, California.  Moreover, it has offices and facilities across the United States, and in the United Kingdom, Hong Kong, China, Vietnam, India, Indonesia and Bangladesh.

Talon was the inventor of the zipper. It proceeded to pioneer a number of innovations customary in zippers today. Talon’s TekFit® is its newest division. TekFit® has exclusive rights to advanced fabric technologies, which facilitate the addition of mechanical stretch into most standard fabrics.

Talon develops, manufactures, and distributes custom zippers exclusively under its Talon® brand (The World's Original Zipper Since 1893). Furthermore, it designs, develops, manufactures, and distributes complete apparel trim solutions and products; and provides stretch technology for specialty waistbands, shirt collars, and other items all under its trademark and internationally renowned brands, Talon®, and TekFit®.

Last week, Talon International reported financial results for Q2 ended June 30, 2017. Revenues for the three months ended June 30, 2017 were $12.9 million. This represents a drop of $1.6 million, or 10.9 percent, versus the same period in 2016.

Talon Zipper sales were $967,000 lower than the same period in 2016. Talon Trim products, which consist mainly of sales to specialty retail branded customers, dropped by $602,000 versus the same period in 2016.  Both business divisions experienced reduced sales to mass merchandising brand customers and specialty retail brands customers.

Net income for the quarter was $604,000 or $0.01 per share versus $958,000, or $0.01 per share, for the quarter ended June 30, 2016.  Net income for the six months ended June 30, 2017 was $610,000. This represents a drop from $1.0 million in the same period in 2016.
Mr. Larry Dyne, Talon International's Chief Executive Officer, stated, “The soft retail, brick & mortar apparel market negatively affected our second quarter performance.  While the environment may continue to be tough in the near future, we remain focused on our corporate initiatives.  By leveraging existing relationships, we are building on new opportunities, both within our Zipper and Trim products.” 

Talon International, Inc. (TALN), closed Monday's trading session at $0.15, down 21.05%, on 121,443 volume with 24 trades. The average volume for the last 60 days is 616,015 and the stock's 52-week low/high is $0.0057/$0.54.

graphic

The QualityStocks
Company Corner

graphic
graphic

AppSwarm, Inc. (SWRM)

The QualityStocks Daily Newsletter would like to spotlight AppSwarm, Inc. (SWRM). Today, AppSwarm, Inc. closed trading at $0.0101, even for the day, on 223,905 volume with 9 trades. The stock’s average daily volume over the past 60 days is 207,617 and its 52-week low/high is $0.002/$0.30.

AppSwarm, Inc. (OTC: SWRM), a technology development and incubation acceleration company that partners up with app developers, is pleased to announce the acquisition of multiplatform games publisher and developer MediaPlay, as well as the creation of two divisions of AppSwarm. Assets purchased include: games in-house, rights to games currently in negotiations, pending letters of intent, pending distribution agreements and work-for-hire contracts.

AppSwarm, Inc. (SWRM) is a technology development and incubation acceleration company that partners up with developers through joint ventures, royalty agreements, marketing partnerships, and outright purchase agreements. Focusing on the ever-growing mobile applications market, the company provides all the resources needed for engagement, retention, virality and monetization.

The global games market generated approximately $100 billion in revenues in 2016, but large global game companies have made it extremely difficult for smaller developers to achieve success in the marketplace. As a result, many great ideas aren't monetized. AppSwarm solves this problem by providing the funding and critical business expertise needed to successfully launch and market new applications.

Business applications is another area of focus for the company. Targeting small to medium sized businesses, AppSwarm will be developing and acquiring mobile application tools and platforms that increase productivity and security via data encryption, cloud storage, content management and delivery, digital payments, automation, and customer loyalty marketing solutions. Recent acquisitions made so far represent only a small example of future planned initiatives to develop and market tools for the business community.

Regardless of the target market, AppSwarm can help developers accelerate the success of their app through funding, technology and marketing expertise, as well as a unique eco system that accelerates user acquisition. The company is able to assist at any state of development with completion of concept, market analysis, business and financial management, direct sales and marketing, social game development to ensure correct product application and expedient deployment with cost efficiency.

Ron Brewer, CEO of the company, has accumulated extensive leadership in the technology sector and brings valuable knowledge gained as a Director of Southbridge Advisory Group for nearly 20 years. Ron's C-level experience includes merger & acquisition and post-acquisition turnaround in both the private and small-cap public sector. John Rabbit, director of finance, is a seasoned business veteran that has worked with Fortune 500 firms and served in CEO, COO and CFO positions for firms ranking from $5 million to $300 million in annual revenues. John was directly involved in numerous acquisitions and served in executive capacities for several multinational subsidiaries.

With a well-suited management team, multiple synergistic revenue streams, and diversified growth strategy, AppSwarm is well positioned in a steadily growing industry with countless opportunities for capitalization. Disclaimer

AppSwarm, Inc. Blog

AppSwarm, Inc. News:

AppSwarm Announces Acquisition of Multiplatform Games Developer and Publisher MediaPlay and the Creation of Two Divisions of AppSwarm, Inc.

AppSwarm, Inc. (SWRM) Ahead of the Game as It Seeks to Increase Choice for More than 2 Billion Players

AppSwarm to Expand into Mobile Business Applications

HighCom Global Security, Inc. (HCGS)

The QualityStocks Daily Newsletter would like to spotlight HighCom Global Security, Inc. (HCGS). Today, HighCom Global Security, Inc. closed trading at $0.0276, up 90.34%, on 1,166 volume with 1 trade. The stock’s average daily volume over the past 60 days is 5,605 and its 52-week low/high is $0.005/$0.10.

HighCom Global Security, Inc. (OTC: HCGS), as part of its corporate restructuring plan to focus on international expansion, is pleased to introduce Craig B. Campbell as its chief executive officer. The Company also announces reorganization of its HighCom Security, Inc. subsidiary and the formation of a new board of directors. These appointments are in conjunction with the Company's official name change and reorganization, reported on August 4, 2017.

HighCom Global Security, Inc. (HCGS) is a manufacturer and distributor of protective products for military and law enforcement personnel. The Corporation operates under two segments, BlastGard Defense Group and Highcom Security.

BlastGard is a blast mitigation specialist with proprietary material proven to effectively mitigate blasts and suppress fires resulting from explosions. The company's patented BlastWrap® technology acts as a "virtual tent" to effectively mitigate blast effects and suppress post-blast fires. This unique technology works by triggering physical and chemical processes to dissipate blast energy, thereby reducing the aftermath of acoustic and shock waves, peak overpressure, reflected peak overpressure, impulse and afterburn. The remaining, significantly reduced energy is transmitted at a slower, more sustainable level. Notably, BlastWrap does not dispense chemical extinguishants; uses neither alarms, sensors, nor an activation system; and is nontoxic and ecologically friendly.

Similarly, the company's BlastGard MTR trash receptacles dramatically reduce lethal threats posed by the detonation of an improvised explosive device (IED). Equipped with Triple Wall Technology, BlastGard MTR mitigates primary fragments, secondary fragments, mechanical effects (shock/blast pressure) and thermal effects (contact and radiation burn) from the fireball, after-burn and resultant post-blast fires.

BlastGard's primary market focus lies on providing blast effects mitigation solutions for customers operating in the commercial sector, military, law enforcement and government agencies. With a vision of being recognized as the leading provider of environmentally responsible solutions to protect lives and structures from the hazards associated with fire and explosions, the company is capable of addressing a wide array of industry applications spanning from fire suppression for naval vessels and merchant ships to protection of buildings against vehicle bombs.

This vision is supported by the ban of Halon extinguishing agents, as outlined in the Montreal protocol, which effectively establishes BlastWrap® as the only blast and fire suppression means available for most applications, including adaptation for underwater use.

The company's position at the head of the blast suppression market has helped BlastGard attain a number of government awards, including designation of its BlastWrap® product as a Qualified Anti-Terrorism Technology and placement on the "Approved Products List for Homeland Security." This designation was extended in early 2017, meaning that BlastWrap® is approved for use by the Department of Homeland Security under the SAFETY Act until November 2021.

HighCom Security, develops, tests, manufactures and distributes body armor and personal protective equipment, including more than two dozen NIJ (National Institute of Justice) compliant hard and soft armor products. Highcom Security has a 20-year history of producing quality armor with no operational failures and no recalls of its American made products.

Highcom Security was founded in 1997 and has produced close to 1 million pieces of armor for the Global community. The company is ISO 9001:2008 certified and the first company in the world to be BA 9000:2012 certified compliant.

For the past decade, Highcom Security has also been able to offer some of the largest armor manufacturers with private label/OEM hard armor solutions for end use by military and law enforcement agencies globally, a market reach obtained because of the company's reputation for innovative technology, exceptional customer service and superior quality performance. Disclaimer

HighCom Global Security, Inc. Blog

HighCom Global Security, Inc. News:

HighCom Global Security Introduces New CEO and Board of Directors as Part of Globally Focused Restructuring Plan

BlastGard International, Inc. Announces Name and Symbol Change to HighCom Global Security, Inc. (HCGS), Rebranding Initiative to Reflect Expanded Growth Strategy

BlastGard International, Inc. (BLGA) Engages NetworkNewsWire for Corporate Communications Solutions

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.0255, up 6.25%, on 1,540,302 volume with 69 trades. The stock’s average daily volume over the past 60 days is 309,153, and its 52-week low/high is $0.0077/$0.04.

Global Payout, Inc. (OTC: GOHE) (the "Company") announced that it has finalized and fully executed a Licensing Agreement with Cagney Global Logistics for the exclusive white labeling and implementation of the Global Reserve Platform. The Platform will be integrated into Cagney's existing delivery and payment component, the Final Mile solution, to enhance its Fortune 500 customer web sales.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout's fully configurable "banking-in-a-box" web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today's banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout's management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and "high-risk" market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and "high-risk" enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout, Inc. Finalizes Licensing Agreement with Cagney Global Logistics for the use of the Global Payout Technology Platform

Global Payout, Inc. and MoneyTrac Technology Enter the Multi-Billion Dollar CBD Market through their Agreement with H Smart, Inc.

Marijuana Company of America Completes $250,000 Investment in MoneyTrac Technology

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.6845, up 0.90%, on 136,043 volume with 74 trades. The stock’s average daily volume over the past 60 days is 44,216 and its 52-week low/high is $0.6171/$0.90.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Goes from RTO to $43 Million in Cash in 3 Months -- CFN Media

ABcann and Cannabis Wheaton Announce Closing of $15 Million Investment

ABcann Global Provides Construction and Expansion Update

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.23, up 7.88%, on 175,919 volume with 102 trades. The stock’s average daily volume over the past 60 days is 386,226, and its 52-week low/high is $0.059/$0.72.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

InMed Announces Publication in European Journal of Pain

InMed Pharma Advances Cannabinoid EB Therapy -- CFN Media

InMed Signs R&D Agreement with ATERA

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

TopPennyStockMovers
(IICN) +107.21%

2.

QualityStocks
(HCGS) +90.34%

3.

Wall Street Mover
(HIPH) +73.91%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251